Thyroid Cancer in a Psoriatic Patient Treated With Secukinumab: A Case Report and Literature Review

Biologics are a key treatment option for managing chronic inflammatory and autoimmune diseases, especially moderate to severe psoriasis. While studies have not definitively proven a causal link between biologics and cancer, concerns remain regarding their potential association with an increased risk of certain malignancies. This report describes an observed temporal association in a patient with psoriasis who was treated with the interleukin-17A inhibitor secukinumab for four years and subsequently developed metastatic medullary thyroid cancer.